Datasea Achieves Breakthrough in Acoustic Technology, Accelerating Billion-Dollar Commercialization in Healthcare
Datasea (NASDAQ: DTSS) announced a significant breakthrough in acoustic technology, integrating sound wave coupling with AI for healthcare applications. The company has developed technology for precise regulation of nervous system functions, including intracranial, peripheral, and cardiac areas, creating a closed-loop ecosystem for medical interventions.
The company is targeting a substantial market opportunity projected to reach over $100 billion in China and $90 billion globally by 2030. Datasea has positioned ultrasound neuromodulation as its core product strategy and has begun initial commercialization phases with medical-grade precision hardware products.
Datasea (NASDAQ: DTSS) ha annunciato un importante avanzamento nella tecnologia acustica, integrando l'accoppiamento delle onde sonore con l'IA per applicazioni sanitarie. L'azienda ha sviluppato una tecnologia per la regolazione precisa delle funzioni del sistema nervoso, comprendendo aree intracraniche, periferiche e cardiache, creando un ecosistema a circuito chiuso per interventi medici.
L'impresa punta a un'opportunit脿 di mercato significativa, stimata oltre 100 miliardi di dollari in Cina e 90 miliardi a livello globale entro il 2030. Datasea ha scelto la neuromodulazione a ultrasuoni come strategia di prodotto principale e ha avviato le fasi iniziali di commercializzazione con dispositivi hardware di precisione per uso medico.
Datasea (NASDAQ: DTSS) anunci贸 un avance significativo en tecnolog铆a ac煤stica, integrando el acoplamiento de ondas sonoras con IA para aplicaciones sanitarias. La compa帽铆a ha desarrollado una tecnolog铆a para la regulaci贸n precisa de las funciones del sistema nervioso, que abarca las 谩reas intracraneal, perif茅rica y card铆aca, creando un ecosistema en bucle cerrado para intervenciones m茅dicas.
La empresa apunta a una oportunidad de mercado sustancial proyectada en m谩s de 100.000 millones de d贸lares en China y 90.000 millones a nivel mundial para 2030. Datasea ha establecido la neuromodulaci贸n por ultrasonido como su estrategia de producto central y ha comenzado las fases iniciales de comercializaci贸n con productos de hardware m茅dico de precisi贸n.
Datasea (NASDAQ: DTSS)電� 鞚岉寣 瓴绊暕瓿� AI毳� 鞚橂鞐� 鞝戨頃� 須嶊赴鞝侅澑 鞚岉枼 旮办垹 氚滌爠鞚� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 霊愱皽雮�, 毵愳磮, 鞁灔 鞓侅棴鞚� 韽暔頃� 鞁犼步瓿� 旮半姤鞚� 鞝曤皜 臁办爤鞚� 鞙勴暅 旮办垹鞚� 臧滊皽頄堨溂氅�, 鞚橂 臧滌瀰鞚� 鞙勴暅 韽愴殞搿滍槙 靸濏儨瓿勲ゼ 甑稌頄堨姷雼堧嫟.
須岇偓電� 2030雲勱箤歆� 欷戧淡鞐愳劀 1,000鞏� 雼煬 鞚挫儊, 鞝� 靹戈硠鞝侅溂搿� 900鞏� 雼煬鞐� 雼暊 瓴冹溂搿� 鞓堨儊霅橂姅 韥� 鞁滌灔 旮绊殞毳� 瓴儱頃橁碃 鞛堨姷雼堧嫟. Datasea電� 齑堨潓韺� 鞁犼步臁办爤鞚� 頃奠嫭 鞝滍拡 鞝勲灥鞙茧 靷缄碃 鞚橂 霌标笁鞚� 鞝曤皜 頃橂摐鞗柎 鞝滍拡鞙茧 齑堦赴 靸侅梾頇� 雼硠鞐� 彀╈垬頄堨姷雼堧嫟.
Datasea (NASDAQ: DTSS) a annonc茅 une avanc茅e majeure en technologie acoustique, int茅grant le couplage d'ondes sonores avec l'IA pour des applications de sant茅. La soci茅t茅 a mis au point une technologie pour la r茅gulation pr茅cise des fonctions du syst猫me nerveux, couvrant les zones intracr芒niennes, p茅riph茅riques et cardiaques, cr茅ant un 茅cosyst猫me en boucle ferm茅e pour les interventions m茅dicales.
La soci茅t茅 vise une opportunit茅 de march茅 importante, estim茅e 脿 plus de 100 milliards de dollars en Chine et 90 milliards 脿 l'茅chelle mondiale d'ici 2030. Datasea a positionn茅 la neuromodulation par ultrasons comme strat茅gie produit principale et a entam茅 les premi猫res phases de commercialisation avec des produits mat茅riels m茅dicaux de pr茅cision.
Datasea (NASDAQ: DTSS) k眉ndigte einen bedeutenden Durchbruch in der Akustiktechnologie an und integriert die Kopplung von Schallwellen mit KI f眉r Gesundheitsanwendungen. Das Unternehmen hat eine Technologie zur pr盲zisen Regulierung von Funktionen des Nervensystems entwickelt, die intrakraniale, periphere und kardiale Bereiche abdeckt und ein geschlossenes 脰kosystem f眉r medizinische Interventionen schafft.
Das Unternehmen zielt auf eine erhebliche Marktchance, die bis 2030 auf 眉ber 100 Milliarden Dollar in China und 90 Milliarden Dollar weltweit gesch盲tzt wird. Datasea hat die Ultraschall-Neuromodulation als Kernproduktstrategie positioniert und mit der anf盲nglichen Kommerzialisierung medizintechnischer Pr盲zisionshardware begonnen.
- Breakthrough in acoustic technology combining sound wave coupling with AI for healthcare applications
- Targeting large market opportunity of $100B in China and $90B globally by 2030
- Successfully developed medical-grade precision hardware products ready for commercialization
- Created closed-loop ecosystem for medical interventions with immediate revenue potential
- Commercialization still in initial phases with unproven market acceptance
- Future plans and business drivers details pending future communications
- Potential regulatory hurdles for medical device approvals not addressed
Insights
Datasea's acoustic technology breakthrough enables nervous system regulation with healthcare applications, targeting a projected $190B market by 2030.
Datasea's announcement represents a potentially significant development in the intersection of acoustic technology and healthcare. The company claims to have achieved integration of sound wave coupling with AI for applications in precision health management and clinical intervention. Their technology reportedly enables precise regulation of nervous system functions across intracranial, peripheral, and cardiac areas, as well as foot acupoint stimulation.
The core technological approach centers on ultrasound neuromodulation, creating what they describe as a closed-loop ecosystem of detection鈥揳nalysis鈥揹iagnosis鈥搑eal-time intervention. This represents an intriguing application of acoustic technology to neurology, though the press release lacks specific details on clinical validation or regulatory approvals.
While the company states they've developed hardware products with "medical-grade precision" and commenced initial commercialization, there's minimal information about actual product specifications, clinical efficacy data, or regulatory status. The press release cites third-party market projections of $100 billion in China and $90 billion globally by 2030 for this application area, but doesn't specify Datasea's projected market share or revenue targets.
The announcement suggests the company is moving from R&D toward commercialization through strategic partnerships, though these partnerships remain unspecified. For a complete assessment, investors would need additional information on clinical validation results, regulatory pathway, commercialization timeline, and specific revenue projections.
Datasea announces acoustic-AI breakthrough targeting healthcare markets, but lacks specifics on revenue timelines, partnerships, and competitive advantages.
Datasea's announcement highlights their pivot toward healthcare applications of acoustic technology, specifically targeting nervous system regulation through their proprietary sound wave coupling technologies. This strategic direction aligns with broader industry trends toward non-pharmaceutical precision health solutions, which the company estimates represents a $190 billion global opportunity by 2030 (citing Grand View Research data).
The press release indicates Datasea has developed hardware products and begun initial commercialization, potentially opening immediate revenue channels. However, it lacks concrete details about specific products, their stage of development, pricing models, or sales projections. The announcement mentions "strategic collaborations" to accelerate technology transfer and product deployment, but provides no details on partners, deal structures, or expected contributions to revenue.
While the company positions ultrasound neuromodulation as its core product strategy, the release offers no competitive landscape analysis. The acoustic healthcare space already has established players and alternative technologies targeting similar applications. Without specific differentiators or proprietary advantages explained, it's difficult to assess Datasea's potential market position.
The vague statement that "further information and regarding business drivers and future plans will be communicated in the near future" suggests the company is still formulating concrete commercialization strategies. The announcement appears designed to highlight technological progress rather than immediate financial impact, with CEO Liu explicitly "inviting capital markets to stay tuned" for more substantive details.
DTSS' Acoustic innovation Addresses the Healthcare Application Market Projected to Exceed
Due to the rapidly growing demand for non-pharmaceutical precision health solutions and increasing policy support for healthcare, the Company is well-positioned to adress a market opportunity projected by research and consulting firm Grand View Research at approximately over
Commercialization Engine Fully Activated
Leveraging its proprietary sound wave coupling technologies, Datasea has realized precise regulation of the nervous system鈥攊ncluding intracranial, peripheral, and cardiac areas鈥攁s well as targeted foot acupoint stimulation. This has enabled the creation of a closed-loop ecosystem of detection鈥揳nalysis鈥揹iagnosis鈥搑eal-time intervention in core medical and health scenarios, with expected high clinical value.
By advancing the convergence of "Acoustics + Neurology," Datasea has positioned ultrasound neuromodulation as its core product strategy. The Company has already developed innovative hardware products and solutions with medical-grade precision, achieved staged results, and commenced the initial phase of commercialization. These efforts not only open immediate revenue channels but also lay the foundation for deep engagement in the trillion-dollar healthcare ecosystem.
Ms. Zhixin Liu, Chief Executive Officer of Datasea, stated:
"This breakthrough in applying acoustic technology to healthcare marks a new stage in our commercialization journey. Through continuous innovation and deep integration with industry applications, we have developed acoustic products and solutions that deliver both clinical value and market potential, and we are fully prepared for commercialization. In order to rapidly advance this breakthrough technology, we are accelerating technology transfer, product deployment, and solution rollout through strategic collaborations. We expect these initiatives to drive sustained growth momentum. Further information and regarding business drivers and future plans will be communicated in the near future,, and we invite the capital markets to stay tuned锛�"
Expanding Access to a Billion-Dollar Market
This commercialization initiative is underpinned by Datasea's strong acoustic technologies, which directly address critical pain points in healthcare industry upgrades. According to industry data provided by global market research firm听International Data Corporation (IDC), relevant acoustic technology subfields are experiencing exponential growth, particularly in precision health management, where innovation is set to drive disruptive transformation.
As a continuous leader in acoustic technology, Datasea will use this breakthrough as a springboard to further advance technological iterations and accelerate the integration of clinical applications. The Company is committed to enabling intelligent upgrades in healthcare, contributing to global wellness, enhancing consumer experiences, and delivering sustainable value to its shareholders.
About Datasea Inc.
Datasea Inc. ("Datasea") is a leading provider of products, services, and solutions for enterprise and retail customers in two innovative industries, acoustic high tech and 5G-AI multimodal digitalization. The Company's advanced R&D technology serves as the core infrastructure and backbone for its products. Its 5G multimodal digital segment operates on a cloud platform based on AI. Datasea leverages cutting-edge technologies, precision manufacturing, and ultrasonic, infrasound and directional sound technology in its acoustics business to combat viruses and prevent human infections, and it is also developing applications in medical ultrasonic cosmetology. In July 2023, Datasea established a wholly-owned subsidiary, Datasea Acoustics LLC, in
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the
Investor and Media Contact:听
Datasea Investor Relations
贰尘补颈濒:听听investorrelations@shuhaixinxi.com
听听听听听听听听听听听听 听 听 听 听 听 听[email protected]听
Precept Investor Relations LLC
David Rudnick
+1 646-694-8538
[email protected]
View original content to download multimedia:
SOURCE Datasea Inc.
FAQ
What is the breakthrough technology announced by Datasea (DTSS)?
What is the market size potential for Datasea's acoustic healthcare technology?
What is Datasea's core product strategy in healthcare?
How is Datasea planning to commercialize its acoustic technology?
What specific healthcare applications has Datasea developed with its acoustic technology?
